K. Williamson

发表

Is There an Expanded Role for Digoxin in Patients with Heart Failure and Sinus Rhythm? A Protagonist Viewpoint

J. H. Patterson, K. Williamson, J. Patterson, 1997, The Annals of pharmacotherapy.

Association Between Angiotensin Receptor–Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction

S. Solomon, I. Piña, G. Felker, 2021, Circulation. Heart failure.

Is There a Role for Digoxin in Patients With Systolic Dysfunction?

K. Williamson, 1996, Pharmacotherapy.

Pharmacogenetics and Heart Failure: A Convergence with Carvedilol

J. H. Patterson, K. Williamson, A. Meadowcroft, 1997, Pharmacotherapy.

Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers

K. Adams, K. Williamson, J. H. Patterson, 1998, Clinical pharmacology and therapeutics.

Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.

S. Solomon, I. Piña, G. Felker, 2019, JAMA.

An Evaluation in Current Clinical Practice

K. Williamson, J. H. Patterson, G. Dunham, 2017 .

Digoxin toxicity: an evaluation in current clinical practice.

K. Williamson, J. H. Patterson, G. Dunham, 1998, Archives of internal medicine.

Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF

S. Solomon, I. Piña, G. Felker, 2021, Circulation.

Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan.

S. Solomon, I. Piña, G. Felker, 2020, Circulation. Heart failure.

Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF Study.

S. Solomon, I. Piña, G. Felker, 2022, Clinical chemistry.

Lack of Gender Differences and Large Intrasubject Variability in Cytochrome P450 Activity Measured by Phenotyping with Dextromethorphan

W. T. Sawyer, K. Williamson, D. Blough, 2001, Journal of clinical pharmacology.

The Effects of Fluvastatin, a CYP2C9 Inhibitor, on Losartan Pharmacokinetics in Healthy Volunteers

K. Williamson, J. H. Patterson, A. Hinderliter, 1999, Journal of clinical pharmacology.

The AHCPR Clinical Practice Guideline for Heart Failure Revisited

K. Adams, K. Williamson, Melissa L. Ellis, 1997, The Annals of pharmacotherapy.

Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction.

Akshay S. Desai, S. Solomon, I. Piña, 2020, JACC. Heart failure.

Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.

Akshay S. Desai, J. McMurray, M. Vaduganathan, 2023, European heart journal.

Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.

Akshay S. Desai, D. Morrow, E. Braunwald, 2023, Journal of the American College of Cardiology.

Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/valsartan versus Valsartan in HFmrEF and HFpEF with a Worsening Heart Failure Event.

D. Morrow, E. Braunwald, R. Starling, 2023, Journal of cardiac failure.